Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.

January 9, 2025

Dana-Farber

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Hematology
- Oncology
- Bone Marrow Transplantation
#2

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation
#3

Fred Hutchinson Cancer Center

Seattle, WA
Key Differentiators
- Hematology
- Bone Marrow Transplantation
- Immunotherapy
#4

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Hematology
- Oncology
- Stem Cell Transplantation

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Top Institutions in Hematology

Dana-Farber Cancer Institute

MD Anderson Cancer Center

Fred Hutchinson Cancer Center

Memorial Sloan Kettering Cancer Center

Original Source(s)

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Related Content

Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

Soluble CD147 in Plasma During Sepsis: Correlation with Disease Severity and Prognostic Implications

The 46th annual meeting of the European society for blood and marrow transplantation: nurses group oral session (NO001-NO015)